N. Deshai

A unified imaging-to-pharmacology AI framework for pulmonary nodule detection, malignancy classification, and mutation-stratified drug validation from low-dose CT scans

Background: Low-dose computed tomography (CT) screening for lung cancer can impose a substantial and clinically under-recognised psychosocial burden, with published studies reporting clinically significant anxiety among 30%–45% of screen-positive individuals, driven by a 96.4% benign false-positive rate and prolonged d...